These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 27516477)

  • 1. Global access to antifungal therapy and its variable cost.
    Kneale M; Bartholomew JS; Davies E; Denning DW
    J Antimicrob Chemother; 2016 Dec; 71(12):3599-3606. PubMed ID: 27516477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
    Papadopoulos G; Hunt S; Prasad M
    J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.
    Merry M; Boulware DR
    Clin Infect Dis; 2016 Jun; 62(12):1564-8. PubMed ID: 27009249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.
    Loyse A; Thangaraj H; Easterbrook P; Ford N; Roy M; Chiller T; Govender N; Harrison TS; Bicanic T
    Lancet Infect Dis; 2013 Jul; 13(7):629-37. PubMed ID: 23735626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A brief review of antifungal therapy for deep fungal infection.
    Muller RJ
    Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):21-5. PubMed ID: 11757847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of systemic fungal infections: alternatives to itraconazole.
    Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the treatment of systemic fungal infections.
    Walsh TJ
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal treatment in patients with cancer.
    Viscoli C; Castagnola E; Machetti M
    J Intern Med Suppl; 1997; 740():89-94. PubMed ID: 9350188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
    Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
    Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral azole drugs as systemic antifungal therapy.
    Como JA; Dismukes WE
    N Engl J Med; 1994 Jan; 330(4):263-72. PubMed ID: 8272088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole.
    Grasela TH; Pasko MT; Goodwin SD; Walawander CA; Blackwelder N; Bruder-Holt RJ
    Ann Pharmacother; 1994 Feb; 28(2):261-70. PubMed ID: 8173148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
    Colombo GL; Morlotti L; Serra G
    Recenti Prog Med; 2005 Sep; 96(9):416-23. PubMed ID: 16229321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole.
    Grasela TH; Goodwin SD; Pasko MT; Walawander CA; Raebel MA
    Ann Pharmacother; 1994 Feb; 28(2):252-60. PubMed ID: 8173147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current drug therapy of systemic mycoses: a review.
    Yonga G
    East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antifungal drugs.
    Med Lett Drugs Ther; 1994 Feb; 36(916):16-8. PubMed ID: 8302208
    [No Abstract]   [Full Text] [Related]  

  • 18. [Choice and use of antifungal drugs].
    Dupont B
    Rev Prat; 2001 Apr; 51(7):752-7. PubMed ID: 11387672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
    van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
    N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral antifungal agents].
    Tarumoto N; Maesaki S
    Nihon Rinsho; 2008 Dec; 66(12):2373-7. PubMed ID: 19069108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.